AIM ImmunoTech Inc., a company specializing in immuno-pharma, revealed the initial outcomes of its recently concluded Rights Offering which ended on March 3, 2026, at 5:00 p.m. EST. The estimated total subscriptions from the Rights Offering are around $1.8 million. AIM ImmunoTech is concentrated on advancing Ampligen® (rintatolimod) to combat late-stage pancreatic cancer, a challenging global health issue. These results are preliminary and await confirmation by the company and its subscription agent, Broadridge Corporate Issuer Solutions, LLC.